Same-Day Antiretroviral Therapy Initiation
NCT04032028 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500
Last updated 2024-11-25
Summary
Data from a total of 2,500 walk-in or referred individuals who have been confirmed (diagnosed) HIV positive and accessing care and treatment services at the hospitals targeted by this study will be examined. The starting period for this project is estimated to be the last quarter (Q4) of fiscal year 2018.
Conditions
- HIV Infections
Sponsors & Collaborators
-
Thai Red Cross AIDS Research Centre
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-01
- Primary Completion
- 2022-07-01
- Completion
- 2025-12-01
Countries
- Thailand
Study Locations
More Related Trials
-
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983 ·Status: RECRUITING
-
Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression
NCT03251690 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
NCT03631732 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic
NCT02437981 ·Status: ENROLLING_BY_INVITATION
-
LA PrEP Impact and Cost-effectiveness (TEAMS)
NCT05774548 ·Status: RECRUITING ·Phase: NA
-
Early ART to Limit Infection and Establishment of Reservoir
NCT02859558 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
NCT05584397 ·Status: ENROLLING_BY_INVITATION
-
ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment
NCT01671982 ·Status: COMPLETED ·Phase: PHASE1
-
Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy
NCT03012607 ·Status: COMPLETED ·Phase: NA
-
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
NCT01266902 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01533259 ·Status: COMPLETED ·Phase: PHASE3
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
NCT04644029 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
NCT00529243 ·Status: COMPLETED ·Phase: PHASE3
-
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
NCT06203132 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
NCT00454337 ·Status: COMPLETED ·Phase: PHASE3
-
Appropriate Timing of HAART in Co-infected HIV/TB Patients
NCT01014481 ·Status: TERMINATED ·Phase: PHASE4
-
Reducing Antiretroviral Treatments
NCT04051970 ·Status: UNKNOWN ·Phase: PHASE3
-
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
NCT05312918 ·Status: UNKNOWN
-
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
NCT01709084 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings
NCT02777229 ·Status: COMPLETED ·Phase: PHASE3
-
Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation
NCT01138241 ·Status: COMPLETED
-
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
NCT00781287 ·Status: TERMINATED ·Phase: PHASE4
-
Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand
NCT00119106 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT05349838 ·Status: COMPLETED ·Phase: PHASE3